WO2022250472A1 - 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물을 포함하는 의약품 용기 - Google Patents
1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물을 포함하는 의약품 용기 Download PDFInfo
- Publication number
- WO2022250472A1 WO2022250472A1 PCT/KR2022/007489 KR2022007489W WO2022250472A1 WO 2022250472 A1 WO2022250472 A1 WO 2022250472A1 KR 2022007489 W KR2022007489 W KR 2022007489W WO 2022250472 A1 WO2022250472 A1 WO 2022250472A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- container
- less
- liquid pharmaceutical
- amount
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 89
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims description 5
- OUNXGNDVWVPCOL-UHFFFAOYSA-N 1-[5-(2,4-difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-N-methylmethanamine Chemical group FC1=C(C=CC(=C1)F)C1=C(C(=CN1S(=O)(=O)C1=CC(=CC=C1)F)CNC)OC OUNXGNDVWVPCOL-UHFFFAOYSA-N 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000011521 glass Substances 0.000 claims description 22
- 229920000858 Cyclodextrin Polymers 0.000 claims description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 14
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 10
- 239000001116 FEMA 4028 Substances 0.000 claims description 7
- 229960004853 betadex Drugs 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000004033 plastic Substances 0.000 claims description 7
- -1 2-hydroxypropyl Chemical group 0.000 claims description 5
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 4
- 229920002545 silicone oil Polymers 0.000 claims description 4
- 239000012929 tonicity agent Substances 0.000 claims description 4
- 239000007951 isotonicity adjuster Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 description 19
- 238000004659 sterilization and disinfection Methods 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000002253 acid Substances 0.000 description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 9
- 239000012669 liquid formulation Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 230000007774 longterm Effects 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000006193 liquid solution Substances 0.000 description 5
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000590002 Helicobacter pylori Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 4
- 229940037467 helicobacter pylori Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical group NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine is As a substance described in Korean Patent Registration No. 10-1613245, it has excellent anti-ulcer activity (i.e., proton pump inhibitory activity, etc.) and Helicobacter pylori (H. pylori) eradication activity and GPCR inhibitory action, thereby treating gastrointestinal ulcers and gastritis , reflux esophagitis, or gastrointestinal damage caused by Helicobacter pylori.
- the present inventors have confirmed that the stability of the composition deteriorates when stored for a long time in a liquid form, and as a result of intensive research on the cause of such a long-term stability problem, the substance reacts with an acid or base to increase degradation products. It was confirmed that, in particular, the acid / base reaction is accelerated in the step of moist heat sterilization, dry sterilization, etc., which are generally required high-temperature sterilization processes in the manufacturing process for liquid formulations, Development of a stable liquid formulation containing Formula 1 described later I had difficulty doing it.
- the inventors of the present invention 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl) -N-methylmethanamine, or a pharmaceutically acceptable salt thereof liquid pharmaceutical composition as a liquid formulation in a standard glass vial, when stored for a long time, there is a possibility that the solution may react with an alkaline substance derived from the inner surface of the vial to ensure stability It was found that it is difficult and this can lead to great difficulties in commercialization, and as a result of efforts to provide a pharmaceutical container for long-term stable storage, when a container of a specific material is used, the reaction between the pharmaceutical composition and the container is minimized and stored The present invention was completed by confirming that it is possible to provide a pharmaceutical product in the form of an easy and ready-to-use liquid preparation for injection, and that it has stability even after undergoing a high-temperature sterilization process.
- the present invention is a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; including a liquid pharmaceutical composition comprising a plastic container; a glass container coated on the inside with silicone oil, SiO 2 , or SiOCH; or a drug container that is a dealkalized glass container.
- the chemical name of the compound represented by Formula 1 is 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrole-3 As -yl)-N-methylmethanamine, it is a substance described in Korean Patent Registration No. 10-1613245.
- the compound represented by Formula 1 is an active ingredient exhibiting pharmacological effects of the liquid pharmaceutical composition of the present invention, and has excellent anti-ulcer activity (i.e., proton pump inhibitory activity, etc.) and Helicobacter pylori (H. pylori) eradication activity and GPCR. By having an inhibitory action, it is a useful substance for preventing and treating gastrointestinal ulcers, gastritis, reflux esophagitis, or gastrointestinal damage caused by Helicobacter pylori.
- a pharmaceutically acceptable salt thereof may be used as an active ingredient exhibiting pharmacological effects of the liquid pharmaceutical composition of the present invention.
- a salt commonly used in the art such as an acid addition salt formed by a pharmaceutically acceptable free acid, may be used without limitation.
- pharmaceutically acceptable salt of the present invention is a concentration that has an effective effect that is relatively non-toxic and harmless to patients, and any of the compounds represented by Formula 1 do not reduce the beneficial effects of the compound represented by Formula 1 by side effects caused by the salt. means any organic or inorganic addition salt of
- a pharmaceutically acceptable salt can be obtained by a conventional method using an inorganic or organic acid.
- the compound represented by Formula 1 is dissolved in a water-miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile, and an organic acid or inorganic acid is added to filter the precipitated crystals, and dried to prepare a pharmaceutical product. to obtain an acceptable salt.
- a water-miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile
- an organic acid or inorganic acid is added to filter the precipitated crystals, and dried to prepare a pharmaceutical product.
- it may be prepared by reducing the solvent or excess acid in the reaction mixture to which acid is added and drying the residue, or by filtering a precipitated salt by adding another organic solvent.
- hydrochloric acid hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, octal and salts derived from mitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid or toluenesulfonic acid, and the like.
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof may react with an acid or base to increase decomposition products, when storing its liquid pharmaceutical composition in a standard container for a long period of time, the product derived from the inner surface of the container There is a possibility of reaction between alkaline substances and solutions. In particular, there is a problem that the above reaction reacts more actively when using a general standard glass container. Therefore, in order to more easily store the liquid formulation for a long period of time, the drug container containing the liquid pharmaceutical composition is a plastic container rather than a glass container, a glass container coated with a specific material functionally, or a dealkalized container is used.
- the plastic container is not particularly limited, but may preferably be a cyclic olefin polymer (COP) or a cyclic olefin copolymer (COC). More preferably, it may be a cyclic olefin polymer.
- COP cyclic olefin polymer
- COC cyclic olefin copolymer
- the inner coating material of the glass container silicon oil, SiO 2 , or SiOCH having low reactivity with the liquid formulation may be used, and acid treatment is performed on the inside of the general glass container to remove alkaline substances from the surface of the container.
- a glass container may be used. In this way, by coating or treating with a specific material, or by using a container of a specific material, the stability of the liquid pharmaceutical composition is increased and commercialization is possible, and it can be usefully used as a ready-to-use injection solution.
- the acid / base reaction may be accelerated in steps such as moist heat sterilization and dry sterilization, which are generally required high-temperature sterilization processes for liquid formulations, but the stability of the compound can be maintained even in these steps if a specific container is used.
- liquid pharmaceutical composition may preferably further include a cyclodextrin and an isotonic agent.
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof has low water solubility and requires an excessive amount of solubilizing agent and organic solvent to prepare a liquid pharmaceutical composition, such as a pharmaceutical composition for injection.
- a liquid pharmaceutical composition having excellent solubility and stability of the compound represented by Formula 1 at the same time is possible by using the above-described components instead of using a solubilizing agent generally used in liquid pharmaceutical compositions. .
- the cyclodextrin is a cyclic oligosaccharide in which 6 to 12 glucose molecules form alpha-1,4-glycosidic bonds and is used as a stabilizer in the present invention.
- the cyclodextrin is beta-cyclodextrin or gamma-cyclodextrin, more preferably beta-cyclodextrin.
- the beta-cyclodextrin is (2-hydroxypropyl)-beta-cyclodextrin or sulfobutylether-beta-cyclodextrin, and its English abbreviations are 'HP- ⁇ -CD' and 'SBE, respectively. - ⁇ -CD'.
- the beta-cyclodextrin is (2-hydroxypropyl)-beta-cyclodextrin (HP- ⁇ -CD).
- the cyclodextrin is suitable for stabilizing the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
- the cyclodextrin is used in an amount of 3.0 to 25.0 parts by weight based on 1 part by weight of the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof. If the content is less than 3.0 parts by weight, stabilization of the compound represented by Formula 1 is not sufficient, and thus rehydration of the liquid pharmaceutical composition is difficult or total related substances increase during long-term storage. In addition, when the content is greater than 25.0 parts by weight, the amount of the stabilizer used is too large, so the viscosity of the liquid pharmaceutical composition may increase or cause hypersensitivity when administered to a patient.
- the amount of the cyclodextrin is 3.5 parts by weight or more, 4.0 parts by weight or more, or 4.5 parts by weight or more based on 1 part by weight of the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; 20.0 parts by weight or less, 19.0 parts by weight or less, 18.0 parts by weight or less, 17.0 parts by weight or less, 16.0 parts by weight or less, 15.0 parts by weight or less, 14.0 parts by weight or less, 13.0 parts by weight or less, 12.0 parts by weight or less, 11.0 parts by weight or less, or 10.0 parts by weight or less.
- the 'isotonic agent' is an additive added to make the osmotic pressure of the liquid pharmaceutical composition contained in the container similar to that of the body. Since the liquid pharmaceutical composition is directly administered into the body without a separate dilution process, it should be prepared at the same osmotic pressure as that of the body in order to reduce side effects when administered into the body.
- the tonicity agent may be sodium chloride (NaCl), D-mannitol, dextrose, glycerin, or KCl (potassium chloride), more preferably, sodium chloride (NaCl), dextrose, glycerin, or KCl (potassium chloride) , and most preferably, it may be sodium chloride (NaCl), dextrose, or KCl (potassium chloride).
- the tonicity agent is preferably included so that the osmolarity of the liquid pharmaceutical composition according to the present invention can be 100 to 700 mOsmol / L depending on the specific substance. More preferably, the osmolarity of the formulation for injection may be 150 to 650 mOsmol/L, 150 to 450 mOsmol/L, 250 to 450 mOsmol/L, or 270 to 420 mOsmol/L.
- the liquid pharmaceutical composition may further include a lyophilization aid.
- a lyophilization aid may be further included.
- the lyophilization aid may be D-mannitol, sucrose, sorbitol, or trihalose, and more preferably, the lyophilization aid may be D-mannitol.
- the lyophilization aid is used in an amount of 3.0 to 25.0 parts by weight based on 1 part by weight of the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof. If the content is less than 3.0 parts by weight, stabilization of the compound represented by Formula 1 is not sufficient, and thus rehydration of the liquid pharmaceutical composition is difficult or related substances increase during long-term storage. In addition, when the content is greater than 25.0 parts by weight, the amount of the lyophilization adjuvant is excessively high, which may increase the viscosity of the liquid pharmaceutical composition or cause hypersensitivity when administered to a patient.
- the lyophilization aid is 3.5 parts by weight or more, 4.0 parts by weight or more, or 4.5 parts by weight or more based on 1 part by weight of the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; 20.0 parts by weight or less, 15.0 parts by weight or less, 13.0 parts by weight or less, 10.0 parts by weight or less, 9.0 parts by weight or less, 8.0 parts by weight or less, 7.0 parts by weight or less, or 6.0 parts by weight or less.
- the lyophilization aid is used in an amount of 0.5 to 5.0 parts by weight based on 1 part by weight of the cyclodextrin. More preferably, the amount of the lyophilization aid is 0.6 parts by weight or more, 0.7 parts by weight or more, or 0.8 parts by weight or more based on 1 part by weight of the cyclodextrin; 4.5 parts by weight or less, 4.0 parts by weight or less, 3.5 parts by weight or less, 3.0 parts by weight or less, 2.5 parts by weight or less, 2.3 parts by weight or less, 2.0 parts by weight or less, 1.9 parts by weight or less, 1.8 parts by weight or less, 1.7 parts by weight or less, 1.6 parts by weight or less, 1.5 parts by weight or less, 1.4 parts by weight or less, 1.3 parts by weight or less, or 1.2 parts by weight or less.
- the solvent of the liquid pharmaceutical composition is distilled water, water for injection, acetate buffer, or physiological saline.
- the pH of the liquid pharmaceutical composition according to the present invention is 4.0 to 6.0, more preferably 5.0 to 6.0. Due to the chemical characteristics of the liquid pharmaceutical composition of the present invention, an additional pH adjusting agent may not be used to adjust the pH.
- the pH adjusting agent is a material that improves the solubility of a poorly water-soluble or insoluble compound by adjusting the pH of the solution by adding it, and a pharmaceutically acceptable acid or alkali is used.
- any one or more of hydrochloric acid, phosphoric acid, sodium hydroxide, potassium hydroxide, potassium monohydrogen phosphate, potassium dihydrogen phosphate, sodium monohydrogen phosphate, sodium dihydrogen phosphate, sodium carbonate, potassium carbonate and triethanolamine may be used.
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is included in the liquid pharmaceutical composition at 1 to 8 mg/mL. That is, the amount of the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is the total volume (mL) of the liquid pharmaceutical composition (mg) of the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof. ) can be defined as the value divided by
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is present in an amount of 2 mg/mL or more, 3 mg/mL or more, or 4 mg/mL or more, or 5 mg/mL or more in the liquid pharmaceutical composition. greater than or equal to mL; Includes less than 7 mg/mL, less than 6 mg/mL, or less than 5.5 mg/mL.
- the 'amount of related substances' to be described later is analyzed by the related substance test method established in accordance with the ICH Guideline Q2 Analytical Validation. Calculate the total amount of related substances through the proportional formula of the peak area of related substances. Specifically, 'the amount of related substances (%)' is '(concentration of standard solution (mg/mL) / concentration of test solution (mg/mL)) * (peak area of related substances in test solution / peak area of standard solution) * 100' can be calculated.
- the amount of related substances generated in the liquid pharmaceutical composition may be 0.5% or less.
- the amount of related substances in the liquid pharmaceutical composition in the pharmaceutical container stored under the harsh conditions for 4 weeks may be 0.48% or less, 0.47% or less, 0.46% or less, or 0.45% or less.
- the difference between the amount of related substances in the liquid pharmaceutical composition measured after storing the drug container under harsh conditions of 60° C. and 80% RH for 4 weeks and the amount of related substances before treatment under harsh conditions may be 0.45% or less.
- the difference between the amount of related substances in the liquid pharmaceutical composition measured after storage for 4 weeks and the amount of related substances before treatment under harsh conditions is 0.43% or less, 0.4% or less, 0.38% or less, 0.36% or less, or 0.35% may be below.
- the pharmaceutical container is heat sterilized at 100 ° C. to 150 ° C. for 3 minutes to 30 minutes, stored at 60 ° C. and 80% RH for 4 weeks, and related substances of the liquid pharmaceutical composition are measured.
- the amount may be less than 0.5%.
- the amount of related substances in the liquid pharmaceutical composition in the pharmaceutical container stored under harsh conditions for 4 weeks after the heat sterilization treatment may be 0.48% or less, 0.47% or less, 0.46% or less, or 0.45% or less. More preferably, the heat sterilization treatment conditions may be 15 minutes at 121 °C, 10 minutes at 126 °C, or 3 minutes at 134 °C.
- the pharmaceutical container is heat sterilized at 100 ° C. to 150 ° C. for 3 minutes to 30 minutes, stored at 60 ° C. and 80% RH for 4 weeks, and related substances of the liquid pharmaceutical composition are measured.
- the difference between the amount and the amount of related substances before treatment with harsh conditions may be less than 0.45%.
- the difference between the amount of related substances in the liquid pharmaceutical composition measured after storage for 4 weeks after the heat sterilization treatment and the amount of related substances before treatment under harsh conditions is 0.43% or less, 0.4% or less, 0.38% or less, 0.36% or less, or 0.35% or less.
- the heat sterilization treatment conditions may be 15 minutes at 121 °C, 10 minutes at 126 °C, or 3 minutes at 134 °C.
- the liquid pharmaceutical composition according to the present invention may further include a preservative, an antioxidant, and the like, and the preservative and antioxidant are not particularly limited as long as they are generally used in the technical field to which the present invention belongs.
- liquid pharmaceutical composition according to the present invention can be prepared by mixing the above-described components except for the solvent in a solvent, and in this process, the order of adding each component to the solvent can be adjusted as necessary, or all components It may be added to the solvent by mixing prior to addition to the solvent.
- the pharmaceutical container of the present invention is 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrole-
- a liquid pharmaceutical composition containing 3-day) -N-methylmethanamine or a pharmaceutically acceptable salt thereof can be stably stored, and the pharmaceutical container containing the liquid pharmaceutical composition can be converted into a ready-to-use injection solution. can be useful
- Each preparation solution was filled in vials of different materials, as shown in Table 2 below, and stored in a harsh condition (60 ° C., 80% RH) chamber for 4 weeks in liquid form, and then stability was evaluated and shown in Table 3.
- the total amount of related substances detected was measured by analyzing the amount of related substances in the liquid solution by HPLC.
- the amount of related substances was analyzed by the related substance test method established in accordance with the ICH Guideline Q2 Analytical Validation.
- the total amount of related substances was calculated through the proportional expression of
- the plastic vials used in #2-9 and #2-10 of Table 2 below are Daikyo Crystal Zenith vials.
- a liquid composition was prepared in the same manner as in Example 1, and stability was evaluated in the same manner as in Example 1.
- the acid-treated glass vial is a vial that has been dealkalized by removing alkaline substances by acid-treating the inner surface of a general glass vial.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
#1-1 | #1-2 | |
API | 40 mg | |
HP-β-CD | 200 mg | |
D-mannitol | 200 mg | |
NaCl | 90 mg | |
주사용수 | 10 mL | |
pH (HCl / NaOH) | 첨가 6.0 |
미첨가 5.0 |
#2-1 | #2-2 | #2-3 | #2-4 | #2-5 | #2-6 | #2-7 | #2-8 | #2-9 | #2-10 | |
API | 40 mg | |||||||||
HP-β-CD | 200 mg | |||||||||
D-mannitol | 200 mg | |||||||||
NaCl | 90 mg | |||||||||
주사용수 | 10 mL | |||||||||
바이알 | 일반 유리바이알 |
실리콘오일코팅된 유리바이알 | SiO2 코팅된 유리바이알 |
SiOCH 코팅된 유리바이알 |
플라스틱바이알 | |||||
pH (HCl / NaOH) | 첨가 6.0 |
미첨가 5.0 |
첨가 6.0 |
미첨가 5.0 |
첨가 6.0 |
미첨가 5.0 |
첨가 6.0 |
미첨가 5.0 |
첨가 6.0 |
미첨가 5.0 |
성상 | 총 유연물질 % | |||
처리 전 | 4주 후 | 처리 전 | 4주 후 | |
#2-1 | 무색 투명한 액 | 무색 투명한 액 | 0.03 | 0.63 |
#2-2 | 무색 투명한 액 | 무색 투명한 액 | 0.05 | 0.51 |
#2-3 | 무색 투명한 액 | 무색 투명한 액 | 0.04 | 0.33 |
#2-4 | 무색 투명한 액 | 무색 투명한 액 | 0.04 | 0.33 |
#2-5 | 무색 투명한 액 | 무색 투명한 액 | 0.04 | 0.19 |
#2-6 | 무색 투명한 액 | 무색 투명한 액 | 0.02 | 0.26 |
#2-7 | 무색 투명한 액 | 무색 투명한 액 | 0.04 | 0.17 |
#2-8 | 무색 투명한 액 | 무색 투명한 액 | 0.04 | 0.12 |
#2-9 | 무색 투명한 액 | 무색 투명한 액 | 0.03 | 0.13 |
#2-10 | 무색 투명한 액 | 무색 투명한 액 | 0.04 | 0.28 |
#2-2 | #3-1 | #3-2 | #3-3 | #2-4 | #3-4 | |
API | 40 mg | |||||
HP-β-CD | 200 mg | |||||
D-mannitol | 200 mg | |||||
NaCl | 90 mg | |||||
주사용수 | 10 mL | |||||
pH (HCl / NaOH) | 미첨가 | |||||
바이알 | 일반 유리바이알 |
산처리 유리바이알 (탈알칼리) | 실리콘오일코팅 된 유리바이알 | |||
습열멸균 (121℃, 15분) |
미적용 | 적용 | 미적용 | 적용 | 미적용 | 적용 |
성상 | 총 유연물질 % | |||
처리 전 | 4주 후 | 처리 전 | 4주 후 | |
#2-2 | 무색 투명한 액 | 무색 투명한 액 | 0.05 | 0.51 |
#3-1 | 무색 투명한 액 | 무색 투명한 액 | 0.20 | 0.88 |
#3-2 | 무색 투명한 액 | 무색 투명한 액 | 0.06 | 0.29 |
#3-3 | 무색 투명한 액 | 무색 투명한 액 | 0.10 | 0.45 |
#2-4 | 무색 투명한 액 | 무색 투명한 액 | 0.04 | 0.33 |
#3-4 | 무색 투명한 액 | 무색 투명한 액 | 0.08 | 0.41 |
Claims (8)
- 제1항에 있어서,상기 액상 약학적 조성물은 사이클로덱스트린 및 등장화제를 추가로 포함하는,의약품 용기.
- 제2항에 있어서,상기 사이클로덱스트린은 (2-하이드록시프로필)-베타-사이클로덱스트린이고,상기 등장화제는 D-만니톨인,의약품 용기.
- 제1항에 있어서,상기 액상 약학적 조성물의 pH는 4.0 내지 6.0인,의약품 용기.
- 제1항에 있어서,상기 의약품 용기를 60℃, 80% RH의 가혹조건에서 4 주간 보관한 뒤 측정한 상기 액상 약학적 조성물의 유연물질 양은 0.5 % 이하인,의약품 용기.
- 제1항에 있어서,상기 의약품 용기를 60℃, 80% RH의 가혹조건에서 4 주간 보관한 뒤 측정한 상기 액상 약학적 조성물의 유연물질 양과 가혹조건 처리 전 유연물질 양의 차이는 0.45 % 이하인,의약품 용기.
- 제1항에 있어서,상기 의약품 용기를 100 ℃ 내지 150 ℃에서 3 분 내지 30 분 간 가열 멸균 처리하고, 60℃, 80% RH의 가혹조건에서 4 주간 보관한 뒤 측정한 상기 액상 약학적 조성물의 유연물질 양은 0.5 % 이하인,의약품 용기.
- 제1항에 있어서,상기 의약품 용기를 100 ℃ 내지 150 ℃에서 3 분 내지 30 분 간 가열 멸균 처리하고, 60℃, 80% RH의 가혹조건에서 4 주간 보관한 뒤 측정한 상기 액상 약학적 조성물의 유연물질 양과 가혹조건 처리 전 유연물질 양의 차이는 0.45 % 이하인,의약품 용기.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112023024653A BR112023024653A2 (pt) | 2021-05-26 | 2022-05-26 | Recipiente de fármaco compreendendo composição farmacêutica líquida de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metóxi-1h-pirrol-3-il)-n-metilmetanamina |
CN202280036629.4A CN117355293A (zh) | 2021-05-26 | 2022-05-26 | 容纳1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺的液体药物组合物的医药容器 |
AU2022280595A AU2022280595A1 (en) | 2021-05-26 | 2022-05-26 | Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
EP22811663.8A EP4349324A1 (en) | 2021-05-26 | 2022-05-26 | Medicine container containing liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
CA3218713A CA3218713A1 (en) | 2021-05-26 | 2022-05-26 | Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
MX2023013985A MX2023013985A (es) | 2021-05-26 | 2022-05-26 | Contenedor de medicina que comprende la composicion farmaceutica liquida de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4- metoxi-1h-pirrol-3-il)-n-metilmetanamina. |
JP2023571145A JP2024519587A (ja) | 2021-05-26 | 2022-05-26 | 1-(5-(2,4-ジフルオロフェニル)-1-((3-フルオロフェニル)スルホニル)-4-メトキシ-1h-ピロール-3-イル)-n-メチルメタンアミンの液状薬学的組成物を含む医薬品容器 |
CONC2023/0018143A CO2023018143A2 (es) | 2021-05-26 | 2023-12-21 | Recipiente para medicamentos que comprende una composición farmacéutica líquida de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0067635 | 2021-05-26 | ||
KR20210067635 | 2021-05-26 | ||
KR1020220064452A KR20220159917A (ko) | 2021-05-26 | 2022-05-26 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물을 포함하는 의약품 용기 |
KR10-2022-0064452 | 2022-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022250472A1 true WO2022250472A1 (ko) | 2022-12-01 |
Family
ID=84228924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/007489 WO2022250472A1 (ko) | 2021-05-26 | 2022-05-26 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물을 포함하는 의약품 용기 |
Country Status (9)
Country | Link |
---|---|
JP (1) | JP2024519587A (ko) |
AU (1) | AU2022280595A1 (ko) |
BR (1) | BR112023024653A2 (ko) |
CA (1) | CA3218713A1 (ko) |
CL (1) | CL2023003478A1 (ko) |
CO (1) | CO2023018143A2 (ko) |
EC (1) | ECSP23089215A (ko) |
MX (1) | MX2023013985A (ko) |
WO (1) | WO2022250472A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07179359A (ja) * | 1994-07-15 | 1995-07-18 | Asahi Chem Ind Co Ltd | 安定なエルカトニン製剤 |
KR101144553B1 (ko) * | 2003-10-03 | 2012-05-11 | 오노 야꾸힝 고교 가부시키가이샤 | (2r)-2-프로필옥탄산을 유효 성분으로 함유하는 약제 |
KR101613245B1 (ko) | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
KR101829705B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성이 향상된 주사용 조성물 |
JP2019089691A (ja) * | 2017-11-15 | 2019-06-13 | 大和特殊硝子株式会社 | ガラス容器 |
-
2022
- 2022-05-26 WO PCT/KR2022/007489 patent/WO2022250472A1/ko active Application Filing
- 2022-05-26 AU AU2022280595A patent/AU2022280595A1/en active Pending
- 2022-05-26 MX MX2023013985A patent/MX2023013985A/es unknown
- 2022-05-26 BR BR112023024653A patent/BR112023024653A2/pt unknown
- 2022-05-26 CA CA3218713A patent/CA3218713A1/en active Pending
- 2022-05-26 JP JP2023571145A patent/JP2024519587A/ja active Pending
-
2023
- 2023-11-22 CL CL2023003478A patent/CL2023003478A1/es unknown
- 2023-11-27 EC ECSENADI202389215A patent/ECSP23089215A/es unknown
- 2023-12-21 CO CONC2023/0018143A patent/CO2023018143A2/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07179359A (ja) * | 1994-07-15 | 1995-07-18 | Asahi Chem Ind Co Ltd | 安定なエルカトニン製剤 |
KR101144553B1 (ko) * | 2003-10-03 | 2012-05-11 | 오노 야꾸힝 고교 가부시키가이샤 | (2r)-2-프로필옥탄산을 유효 성분으로 함유하는 약제 |
KR101613245B1 (ko) | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
KR101818704B1 (ko) * | 2015-04-27 | 2018-02-21 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
KR101829705B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성이 향상된 주사용 조성물 |
JP2019089691A (ja) * | 2017-11-15 | 2019-06-13 | 大和特殊硝子株式会社 | ガラス容器 |
Also Published As
Publication number | Publication date |
---|---|
CA3218713A1 (en) | 2022-12-01 |
ECSP23089215A (es) | 2023-12-29 |
AU2022280595A1 (en) | 2023-11-09 |
CO2023018143A2 (es) | 2023-12-29 |
BR112023024653A2 (pt) | 2024-02-27 |
CL2023003478A1 (es) | 2024-05-31 |
MX2023013985A (es) | 2023-12-12 |
JP2024519587A (ja) | 2024-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018056720A1 (ko) | 안정성이 향상된 주사용 조성물 | |
SK282032B6 (sk) | Kompozícia na báze solí arylheterocyklických zlúčenín | |
KR920003331B1 (ko) | 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법. | |
HU226778B1 (en) | Injection and injection kit containing omeprazole and its analogs | |
RU2566262C2 (ru) | Стабилизированная композиция вориконазола | |
RU2286782C2 (ru) | Препарат замещенных бензимидазолов | |
WO2021125874A1 (ko) | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루우로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물 | |
WO2018164513A1 (ko) | 보르테조밉을 포함하는 안정한 제제 및 이의 제조방법 | |
WO2019009661A1 (en) | SKIN INJECTION COMPOSITION | |
WO2015102315A1 (ko) | 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법 | |
US5750131A (en) | Ifosfamide lyophilizate preparations | |
WO2022250472A1 (ko) | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물을 포함하는 의약품 용기 | |
WO2018021833A1 (ko) | 안정성 및 용해도가 개선된 주사용 조성물 | |
WO2022250469A1 (ko) | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민을 포함하는 신규한 주사용 제제 | |
KR20220159917A (ko) | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물을 포함하는 의약품 용기 | |
Den Brok et al. | Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285. HCl. | |
KR20220159916A (ko) | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민을 포함하는 신규한 주사용 제제 | |
WO2019177320A1 (ko) | 우수한 안정성을 갖는 폴마콕시브 함유 주사액 조성물 및 이의 제조방법 | |
WO2014157989A1 (ko) | 보리코나졸이 함유된 안정화된 조성물 | |
WO2022235048A1 (ko) | 에피나코나졸을 함유하는 액상 형태의 약학적 조성물 | |
WO2014104546A1 (ko) | 안정성이 개선된 옥사세펨 제제 및 그 제조방법 | |
KR100467100B1 (ko) | 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1H-피롤-1-릴)-1H-벤즈이미다졸 또는 이의 Nа염을 함유하는주사제의 제조방법 | |
CN111973562A (zh) | 一种注射用艾司奥美拉唑钠及其制备方法 | |
HU195424B (en) | Process for the production of medical solutions containing l-3,4-dihydroxi-phenil-alpha-methil-alanine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22811663 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022280595 Country of ref document: AU Ref document number: 2022280595 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3218713 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022280595 Country of ref document: AU Date of ref document: 20220526 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: P6002955/2023 Country of ref document: AE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023571145 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 003079-2023 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280036629.4 Country of ref document: CN Ref document number: 2301007624 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/013985 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023/0799.1 Country of ref document: KZ |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023024653 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523451361 Country of ref document: SA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023128224 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022811663 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022811663 Country of ref document: EP Effective date: 20240102 |
|
ENP | Entry into the national phase |
Ref document number: 112023024653 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231124 |